Chairman Huh, Il Sup Vice chairman Cho, Soon Tae CEO President Rhee, Byung Geon President Huh, Eun Chul Business Manufacturing and sales of medicine and medical supplies, etc. Product Portfolio ◦ Hunterase (Hunter syndrome drug) Shinbaro : For the treatment(Enzyme I.V.-Globulin SN inj. Including high purity Replacement Therapy) of Hunter IgG immune function improved syndrome (Mucopolysaccharidosis II) formulation Shinbaro (Osteoarthritis) Urokinase-GCC inj. Cerebral I.V. Hepabig inj. GreenGene F inj. 500I.U. Hemophilia A Green Gene inj. Hemophilia A patients Japanese Encephalitis Vaccine-GCC patients with bleeding symptom control with drug inj. Prevention of Japanese and hemostasis encephalitis Varicella Vaccine-GCC inj. For Varicella-Zoster Immune prophylaxis of Varicella inj. Passive immunization against GC FLU pre-filled syringe inj. Prevention of chickenpox formulation influenza (flu) Hepabig inj. Hepatitis B vaccination Albumin inj. 20%-GCC: Sero-Tet Circulation Authority Executive Hypoalbuminemia drug Summary Company Milestones ◦ Year 1971 Produced the first plasma fractionation droduct. nation’s 1983 Developed Hepavax B, the Hepatitis B vaccine. world’s 3rd 1990 Established the Korea Hemophilia Foundation. 1993 Developed the 2nd varicella vaccine. world’s 1995 Established Green Cross China. 2008 Developed GreenGene, the 4th recombinant Factor for hemophilia A. world’s Ⅶ 2009 Established Green Cross America(GCAM). 2012 Developed Hunterase, the 2nd treatment for Hunter syndrome. world’s 2013 Signed a contract with the Thai Red Cross for plasma fractionation plant project.
CEO Chairman Huh, Il Sup Vice chairman Cho, Soon Tae President Rhee, Byung Geon President Huh, Eun Chul Business Manufacturing and sales of medicine and medical supplies, etc. ◦ Product Portfolio I.V.-Globulin SN inj. Including high purity IgG immune function improved formulation Hunterase (Hunter syndrome drug) Shinbaro : For the treatment(Enzyme Replacement Therapy) of Hunter syndrome (Mucopolysaccharidosis II) Shinbaro (Osteoarthritis) Urokinase-GCC inj. Cerebral I.V. Hepabig inj. GreenGene F inj. 500I.U. Hemophilia A patients with bleeding symptom control and hemostasis Green Gene inj. Hemophilia A patients with drug Japanese Encephalitis Vaccine-GCC inj. Prevention of Japanese encephalitis GC FLU pre-filled syringe inj. Prevention of influenza (flu) Varicella Vaccine-GCC inj. For prophylaxis of Varicella Varicella-Zoster Immune inj. Passive immunization against chickenpox formulation Sero-Tet Circulation Authority Executive Summary Hepabig inj. Hepatitis B vaccination Albumin inj. 20%-GCC: Hypoalbuminemia drug ◦ Company Milestones Year 1971 Produced the nation’s first plasma fractionation droduct. 1983 Developed Hepavax B, the world’s 3rd Hepatitis B vaccine. 1990 Established the Korea Hemophilia Foundation. 1993 Developed the world’s 2nd varicella vaccine. 1995 Established Green Cross China. 2008 Developed GreenGene, the world’s 4th recombinant Factor Ⅶ for hemophilia A. 2009 Established Green Cross America(GCAM). 2012 Developed Hunterase, the world’s 2nd treatment for Hunter syndrome. 2013 Signed a contract with the Thai Red Cross for plasma fractionation plant project.